Revital.co.uk is currently password-protected and directing customers with unfulfilled orders to Bailey Ahmad Business Recovery (BABR) at revital@babr.co.uk, following two creditors' meeting notices published in the London Gazette for Revital Limited in April 2026 (Notice 5108823, 9 April 2026; Notice 5119570, 23 April 2026). This page summarises what the public record shows about Revital's status, and explains where UK customers can buy CDS22-formula — marketed as the original De Simone Formulation, 8 strains, 450 billion CFU — with next-day DPD delivery from Probiotic.co.uk, the authorised UK distributor.

Clinical trials on the De Simone Formulation — an 8-strain, 450 billion CFU probiotic blend — demonstrate statistically significant reductions in abdominal bloating and flatulence in IBS patients (Kim et al., Mayo Clinic, 2003 and 2005). This evidence-based guide covers the gut microbiome science behind bloating, strain-specific RCT data, and how UK consumers can identify a clinically researched probiotic for bloating and gas.

Looking for a VSL3 alternative in the UK? The original De Simone Formulation — the 8-strain probiotic blend used in over 80 clinical trials and referenced in ECCO IBD guidelines — was once sold as VSL#3, then as Vivomixx. It is now available in the UK as CDS22-formula. Same strains. Same 450 billion CFU potency. New name. This guide explains the full brand history, the 2016 commercial split, and why CDS22 is the only product in the UK today carrying the original clinically-studied De Simone Formulation.

The De Simone formulation has demonstrated statistically significant remission rates in ulcerative colitis in multiple randomised controlled trials, including studies referenced in ECCO IBD guidelines. CDS22 is the only UK product containing the original 8-strain formula at 450 billion CFU, previously sold as VSL#3 and Vivomixx.

Intensive bowel support protocols use high-CFU multi-strain probiotics during active flares of IBD, IBS, and pouchitis, with the De Simone formulation studied at doses up to 3,600 billion CFU in clinical trials. CDS22 is available in the UK at 450 billion CFU per sachet and 112 billion CFU per capsule, making it the highest-potency De Simone formulation accessible to UK patients.

The De Simone formulation comprises 8 specific strains — including Lactobacillus acidophilus DSM 24735 and Bifidobacterium longum DSM 24736 — developed by Professor Claudio De Simone and separated from VSL#3 via US and Italian court rulings in 2016. CDS22 is the current authorised UK product containing this formulation, with the legal timeline, strain certificates, and clinical trial index documented in this reference guide.

This pharmacy-grade guide applies strain-specific evidence, CFU viability, storage requirements, and UK regulatory criteria to evaluate leading probiotic products including CDS22, Symprove, Optibac, and Alflorex. Antibiotic timing protocol covered: 2-hour separation rule, 7–14 days post-course continuation, with reference to NHS and FSA guidance.

UK guide: Can you take probiotics with antibiotics? Yes — 2-hour gap rule recommended. Continue 7–14 days post-course. Antibiotic-associated diarrhoea risk 5–30%. Evidence reviewed for Lactobacillus rhamnosus GG and Saccharomyces boulardii with NHS and FSA regulatory context.

CDS22 sachets deliver 450 billion CFU across 8 clinically studied De Simone strains versus Optibac Every Day's 5 billion CFU single-strain formula. This comparison covers strain diversity, clinical trial evidence, and cost-per-dose for UK buyers choosing between everyday maintenance and specialist gut support.

The De Simone formulation is the only probiotic referenced in ECCO IBD guidelines for ulcerative colitis and pouchitis, with remission data from multiple randomised controlled trials including Gionchetti 2000 and Mimura 2004. CDS22 contains the original 8 De Simone strains at 450 billion CFU and is the only UK product carrying this clinically studied formulation.

CDS22 delivers 450 billion CFU across 8 De Simone strains with clinical trial evidence for IBS, ulcerative colitis, and pouchitis; Symprove is a liquid single-strain formula studied primarily in IBS-D. This comparison covers delivery mechanism, strain specificity, CFU potency, and clinical evidence for UK buyers.

Vivomixx Neo uses a different strain profile to the original De Simone formulation and has no independent clinical trial history for IBS or ulcerative colitis. CDS22 contains the original 8 De Simone strains at 450 billion CFU, separated from the Vivomixx brand following European court rulings on formulation IP ownership.